Epidemiology and treatment status of hepatitis C virus infection among people who have ever injected drugs in Korea: a prospective multicenter cohort study from 2007 to 2019 in comparison with non-PWID

التفاصيل البيبلوغرافية
العنوان: Epidemiology and treatment status of hepatitis C virus infection among people who have ever injected drugs in Korea: a prospective multicenter cohort study from 2007 to 2019 in comparison with non-PWID
المؤلفون: Kyung-Ah Kim, Da hye Paik, Gwang Hyun Choi, In Hee Kim, Moran Ki, Sung Bum Cho, Eun Sun Jang, Young Seok Kim, Sook-Hyang Jeong, Youn Jae Lee, Hwa Young Choi
المصدر: Epidemiology and Health
بيانات النشر: Korean Society of Epidemiology, 2021.
سنة النشر: 2021
مصطلحات موضوعية: Male, medicine.medical_specialty, Epidemiology, Hepatitis C virus, Hepacivirus, medicine.disease_cause, Antiviral Agents, Cohort Studies, Treatment status, Internal medicine, Treatment uptake, medicine, Humans, Prospective Studies, Risk factor, Substance Abuse, Intravenous, business.industry, General Medicine, Hepatitis C, Hepatitis C, Chronic, medicine.disease, Pharmaceutical Preparations, Drug users, Cohort, Lifetime risk, Original Article, business, Cohort study
الوصف: OBJECTIVES: Injection drug use is a major risk factor for hepatitis C virus (HCV) infection; however, limited data on this topic are available in Korea. Thus, this study aimed to investigate the epidemiological and clinical characteristics, treatment uptake, and outcomes of HCV infection among people who inject drugs (PWID).METHODS: We used the data from the Korea HCV cohort, which prospectively enrolled patients with HCV infection between 2007 and 2019. Clinical data and results of a questionnaire survey on lifetime risk factors for HCV infection were analyzed according to a self-reported history of injection drug use (PWID vs. non-PWID group).RESULTS: Among the 2,468 patients, 166 (6.7%) were in the PWID group, which contained younger patients (50.6±8.2 vs. 58.2±13.1 years) and a higher proportion of male (81.9 vs. 48.8%) than the non-PWID group. The distribution of PWID showed significant regional variations. Exposure to other risk factors for HCV infection was different between the groups. The proportion of patients with genotype non-2 infection was higher in the PWID group. Treatment uptake was higher in the PWID group in the interferon era; however, it was comparable between the groups in the direct-acting antiviral era. The rate of sustained virological response did not significantly differ between the groups.CONCLUSIONS: As of 2019, PWID constituted a minority of HCV-infected people in Korea. The epidemiological characteristics, but not treatment uptake and outcomes, were different between the PWID and non-PWID groups. Therefore, active HCV screening and treatment should be offered to PWID in Korea.
اللغة: English
تدمد: 2092-7193
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc7e6eb7cfd782d93a0d594b18dd1832
http://europepmc.org/articles/PMC8666681
حقوق: OPEN
رقم الأكسشن: edsair.doi.dedup.....fc7e6eb7cfd782d93a0d594b18dd1832
قاعدة البيانات: OpenAIRE